《新股表現》貝康醫療(02170.HK)暗盤高開46%報40元
根據輝立交易平台顯示,下周一(8日)掛牌的貝康醫療-B(02170.HK)暗盤高開46%報40元欠承接,現造34元,較上市價27.36元,高24%,成交59萬股。
蘇州貝康醫療是內地輔助生殖基因檢測解決方案創新平台,旗下PGT-A試劑盒是首個也是唯一獲國家藥監局批准三代試管嬰兒基因檢測試劑盒。是次來港上市共發售6,666.7萬股H股,並已引入包括清池資本、奧博資本、CRF、Affin Hwang Capital、WinTwin Capital、睿遠基金及常春藤資產管理7名基石投資者,合共認購2,550.25萬股(設6個月禁售期);其中10%公開發售獲近402倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率10%;股份以招股範圍(26.36-27.36元)上限定價,料集資淨額約17.17億元,主要用作核心產品PGT-A試劑盒、PGT-M試劑盒臨床試驗、註冊申報及商業化、開發其他產品及提升研發能力等。上市獨家保薦人中信里昂證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.